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There is already broad recognition of the challenges
of cancer screening during the COVID-19 pandemic.
However, if the current situation last, we anticipate that
thousands of cases will be diagnosed late or in some
cases will be missed. Herein, we discuss the ramifications
of pausing cancer screening programs and turn a spot-
light to advocate for maintaining the early detection
programs running. This will hopefully prevent a ‘cancer
boom’ that will meet an exhausted health system after
the SARS-CoV-2 pandemic will subside.
Dear Editor
The outbreak of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), which originated in
Wuhan, China in late 2019, has become a major concern
all over the world. By March 11, 2020, the number of
cases of SARS-CoV-2 infection outside China had
increased 13-fold, and the number of affected countries
had tripled. With more than 118,000 people affected by
the virus worldwide and 4291 deaths, the World Health
Organization announced that the outbreak of corona-
virus disease 2019 (COVID-19) was a pandemic [1].
Shortly after the pandemic declaration, medical boards
and societies released guidelines stating that medical
professionals should use their clinical judgement when
scheduling elective surgeries and procedures [2]. As
shortages of personal protective equipment aggravated
the insufficiencies of healthcare systems, many hospital
and healthcare providers decided to stop all elective
activity, including cancer screening [3].
The role of cancer screening in early detection and its
impact on survival is well documented in breast, cervi-
cal, lung, and colorectal cancers [4]. Consequently, in-
surers and health officials use cancer screening
participation rates as an index for the quality of care. As
a result, the number of people screened for cancer and
diagnosed at an early stage has been growing steadily
[4]. For the first time, cancer screening has been globally
interrupted. As the number of new COVID-19 cases,
related deaths, and affected countries increases, in-
terruptions of cancer screening schedules are expected to
last [5]. This presents oncologists with some* Corresponding author.
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unprecedented challenges. We realize that resources will
be limited until the return to a normal state and that
treating established, diagnosed patients should be
prioritized. However, we anticipate that the gap in
cancer screening will result in delayed diagnoses, an
increased proportion of patients presenting with
advanced disease, delays in treatment, and, eventually,
detrimental effects on survival. Here we discuss the
potential ramifications of delaying cancer screening.
In the absence of data on the effects of diagnosis delays
in asymptomatic individuals eventually diagnosed with
cancer, our knowledge is based on the existing evidence on
the effects of treatment delays. Some screenable malig-
nancies, such as cervical and prostate cancer, are slow
growing, and screening aims to detect asymptomatic pre-
cancerous lesions; in such cases, a few months’ delay in
diagnosis might have minimal impact on outcomes [6,7].
However, other malignancies, for instance breast and lung
cancers, progress rapidly, so any delay in diagnosis or
treatment risks adverse outcomes [8]. Interestingly, the
literature on treatment delays in colorectal cancer is
inconclusive; in accordancewith some publications, delays
of up to 8 months might even go unnoticed [9,10]. This
further highlights the need for informed decision-making
about resource sharing when the healthcare system re-
covers from the SARS-CoV-2 pandemic.
More than 70% of women between ages 50 and 74 in
the U.S. reported a recent mammogram, and similar
rates were noted in other Western countries [11,12].
There are nearly 50 million women in this age range in
the U.S., which means that 1,412,000 women have
mammograms each month. Based on a recent cross-
national comparison of screening mammography accu-
racy measures, the positive predictive value (i.e., the
number of screening-detected breast cancers divided by
the number of recalls due to positive mammographic
findings) in the U.S. is 4.9% (range: 4.8e16.7%) [13]; and
the number of women who need to be recalled to un-
dergo an invasive procedure to detect 1 breast cancer in
the U.S. is 20.3 (range: 6 to 20.7) [14]. Thus, for each
month that breast cancer screening programs are shut
down due to the SARS-CoV-2 pandemic, 69,629 pa-
tients with breast cancer will go undiagnosed, increasing
their risk for delayed treatment and poor prognosis [15].
Lung cancer is a time-sensitive malignancy; it is
estimated that early-stage lung cancer diagnosis could
save more than 70,000 lives a year [16]. The average 5-
year survival rate for lung cancer (17%) is among the
lowest of all types of cancer but is higher (52%) when the
disease is diagnosed at an early, asymptomatic stage.
However, only 15% of lung cancer cases are diagnosed
at such a stage [17]. In accordance with the U.S. Census
data, 13.2% of adults aged 55e80 years nationwide are
eligible for low-dose computed tomography lung cancer
screening. Given national participation rates, each
month approximately 25,000 adults are screened, and
more than 1200 patients with positive screening results
are diagnosed with lung cancer [18].
The large numbers of patients eligible for screening
will make it difficult for screening programs to recu-
perate once they resume their normal schedules, espe-
cially as the duration of the pandemic increases.
Moreover, with the large expected financial ramifica-
tions of the pandemic, funds directed towards screening
efforts are at risk of being diverted to other causes even
after the pandemic is over. At first glance, the cost of
screening programs appears higher than delaying treat-
ment until there is clinical evidence of disease, owing to
the number needed to screen for each of the screening
tests. However, previous studies have demonstrated that
cost of a screening program increases the cost of care in
exchange for decreased patient morbidity and mortality
[19e23]. In breast, for example, cost of care with a
screening program is estimated to be $63 billion (2000
USD) more than cost of care without a screening pro-
gram over 10 years [23]. However, this results in a gain
of 1.7 million quality-adjusted life-years (QALYs), with
an estimated incremental cost-effectiveness ratio (ICER)
of $37,000 USD per QALY. Generally, an ICER of less
than $50 000 USD per QALY is accepted as a price
worth paying for a decrease in patient morbidity and
mortality. Lung cancer screening programs have also
been demonstrated to be cost-effective, with an esti-
mated ICER of $49,200 USD per QALY [22]. Thus,
although cancer screening efforts result in increased
upfront expenses, the longer term benefits to patient
quality of life and longevity need to be considered.
As the duration of the SARS-CoV-2 pandemic in-
creases, the backlog of patients awaiting their routine
screening will also increase. In the intervening time period,
patients may develop clinical disease, and we may face an
increasing proportion of patients presenting with
advanced-stage breast and lung cancer that will require
multimodal treatment and will cause increased morbidity
and mortality. Although the absolute costs of screening
efforts exceed those of no screening, consideration of the
quality life-years gained is essential to the long-term well-
ness of the population. The SARS-CoV-2 pandemic has
created a new reality that many of us have not experienced
before. Given the amount of uncertainty, the aggressive
response of most health authorities was needed. Today, a
fewweeks into thecrisis, asdataaccumulates,westill donot
know how long the pandemic will last, and this ‘knee-jerk’
response should be revisited. Considering the lower mor-
tality rate of COVID-19 than of breast or lung cancer in
similarly aged populations, the postponement of time-
sensitive screening tests should be avoided or at list mini-
mized. As resources are diverted to treat the acute needs of
patients with COVID-19, a thoughtful approach is needed
to determine how to allocate any remaining resources to
usual healthcare functions. Especially in the aftermath of
the pandemic, we can expect a large surge in healthcare
activityassystemsattempttoplay ‘catch-up’ for themonths
M. Amit et al. / European Journal of Cancer 134 (2020) 86e89 87
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on August 14, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
dedicatedtofightingthepandemic. It is easyto imagine that
cancer screeningmay become a low priority and be further
deferred. However, considering the prognostic effect, cost-
utility ramifications, and the large populations affected,
cancer screening needs to be continually brought to the
tablewhen consideringhow toallocate rare resources.Risk
stratification strategies may need to be refined and used to
triage patients within disease systems to identify those who
might benefit most from screening efforts. Most impor-
tantly, cross-disciplinary discussions need to be open and
collaborative toallowforanorganizedand thoughtfulplan
to optimally distribute resources for the benefit of the
population.Cancer screeningprogramsmayneed tomerge
their efforts to jointly prioritize screening resources to
minimize long-termmorbidity andmortality for the largest
group of patients at the lowest cost.
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